Venetoclax Combined With Azactidine in the Treatment of ALAL

PHASE2RecruitingINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

July 1, 2023

Primary Completion Date

December 1, 2025

Study Completion Date

December 1, 2025

Conditions
Acute Leukemia of Ambiguous Lineage
Interventions
DRUG

Venetoclax

Venetoclax orally once daily (100 mg d1, 200 mg d2, 400 mg d3-28);

DRUG

azactidine

azacitidine 75 mg/m2 subcutaneously once daily on days 1-7

Trial Locations (1)

Unknown

RECRUITING

The First Affliated Hospital of Soochow University, Suzhou

All Listed Sponsors
collaborator

Jining Medical University

OTHER

collaborator

The Second People's Hospital of Huai'an

OTHER

collaborator

The First Affiliated Hospital of Bengbu Medical University

OTHER

collaborator

Affiliated Hospital of Nantong University

OTHER

collaborator

Suzhou Hospital of Traditional Chinese Medicine

OTHER

collaborator

Northern Jiangsu People's Hospital

OTHER

lead

Sheng-Li Xue, MD

OTHER